|
Hemato-oncology
Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
Hye Sung Won, Yong Seok Kim, Jeong Soo Kim, Eun Deok Chang, Sae Jung Na, In Yong Whang, Dong Soo Lee
Korean J Intern Med. 2020;35(6):1489-1496. Published online February 21, 2020
Background/Aims: We evaluated the efficacy of docetaxel and epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer and assessed the predictive factors for response to neoadjuvant chemotherapy and prognostic factors related to relapse-free survival.
Methods: Forty patients who rece..
|
|
|
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Moon Jin Kim, Sung Min Kim, Hyun Ae Jung, Jung Yong Hong, Won Jin Chang, Moon Ki Choi, Hye Sook Kim, Jong-Mu Sun, Keunchil Park, Myung-Ju Ahn
Korean J Intern Med. 2019;34(5):1107-1115. Published online June 20, 2018
Background/Aims: We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Methods: In this study, 18 patients with previously diagnosed R/M HNSCC we..
|
|
|
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
Ji Hyun Lee, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hojin Lee, Hye Jung Lee, Hyo-Jin Kim
Korean J Intern Med. 2013;28(3):314-321. Published online May 1, 2013
Background/AimsTo determine the efficacy and toxicity of docetaxel as a third-line therapy for patients with relapsed gastric cancer who have undergone modified oxaliplatin-fluorouracil (m-FOLFOX)-4 and modified irinotecan-fluorouracil (m-FOLFIRI) regimens.
|
|
|
Docetaxel Monotherapy as Second-Line Treatment for Pretreated Advanced Non-Small Cell Lung Cancer Patients
Yoon Ho Ko, Myung Ah Lee, Yeong Seon Hong, Kyung Shik Lee, Hyun Jin Park, Ie Ryung Yoo, Yeon Sil Kim, Young Kyoon Kim, Keon Hyun Jo, Young Pil Wang, Kyo Young Lee, Jin Hyoung Kang
Korean J Intern Med. 2007;22(3):178-185. Published online September 30, 2007
BackgroundSecond-line chemotherapy offers advanced non-small cell lung cancer (NSCLC) patients a small, but significant increase in survival. Docetaxel is usually administered as a 3-week schedule, yet there is significant toxicity with this therapy. Therefore, a weekly schedu..
|
|
|
